Synthesis of glycyrrhizin analogues as HMGB1 inhibitors and their activity against sepsis in acute kidney injury

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2023-11-05 DOI:10.1016/j.ejmech.2023.115696
Xin Qiang , Yijie Peng , Zongyuan Wang, Wenjie Fu, Wei Li, Quanyi Zhao, Dian He
{"title":"Synthesis of glycyrrhizin analogues as HMGB1 inhibitors and their activity against sepsis in acute kidney injury","authors":"Xin Qiang ,&nbsp;Yijie Peng ,&nbsp;Zongyuan Wang,&nbsp;Wenjie Fu,&nbsp;Wei Li,&nbsp;Quanyi Zhao,&nbsp;Dian He","doi":"10.1016/j.ejmech.2023.115696","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Glycyrrhizin<span> (GL) is one of the antagonists of highly conserved nuclear protein (HMGB1). The researches have shown that the </span></span>glycosyl<span><span> of GL is an important pharmacophore for GL binding to </span>HMGB1, and it is the determinant factor for mechanism of action. To get the HMGB1 inhibitors with higher activity and good </span></span>pharmacokinetic<span> properties, two classes of GL analogues containing C-N glycoside<span> bond were synthesized, and their anti-inflammatory, anti-oxidative stress and anti-septic kidney injury were evaluated. The results are as follows. First, in the anti-inflammatory assay, all the compounds inhibited NO release in some degree; among them, compound </span></span></span><strong>6</strong> displayed the strongest NO inhibitory effect with IC50 value of 15.9 μM, and compound <strong>15</strong><span><span> with IC50 of 20.2 μM. The two compounds not only decreased IL-1β and TNF-α levels in RAW264.7 cells and HK-2 cells, but also downregulated the levels of NLRP3<span>, P-NF-κB p65 and HMGB1 in activated HK-2 cells in a dose-dependent manner. Second, in the renal protection assay with H2O2-stimulated HK-2 cell line, they reduced </span></span>MDA<span> level and increased SOD in HK-2 cells; additionally, they also inhibited the HK-2 cell apoptosis and downregulated the Caspase-1 p20 level. Third, in the </span></span><em>in vivo</em> activity tests of the septic mouse, they also showed good activities just like <em>in vitro</em><span><span>, decreasing the IL-1β, TNF-α, MDA, blood creatinine<span> (Scr) and urea nitrogen (BUN) in serum, and increasing SOD levels in a dose-dependent manner. The immunoblotting<span> results showed the two compounds downregulated the levels of HMGB1, P-NF-κB p65, NLRP3 and Caspase-1 p20 protein. All in all, the two compounds improved the renal injury of septic mice, and alleviated the tube wall structure damage and renal tubular dilation in kidney, which further proved by H&amp;E staining. This suggests the two compounds have septic </span></span></span>acute kidney injury activity, and they will be potential therapeutic drugs for septic acute kidney injury.</span></p></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"259 ","pages":"Article 115696"},"PeriodicalIF":6.0000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523423006633","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 1

Abstract

Glycyrrhizin (GL) is one of the antagonists of highly conserved nuclear protein (HMGB1). The researches have shown that the glycosyl of GL is an important pharmacophore for GL binding to HMGB1, and it is the determinant factor for mechanism of action. To get the HMGB1 inhibitors with higher activity and good pharmacokinetic properties, two classes of GL analogues containing C-N glycoside bond were synthesized, and their anti-inflammatory, anti-oxidative stress and anti-septic kidney injury were evaluated. The results are as follows. First, in the anti-inflammatory assay, all the compounds inhibited NO release in some degree; among them, compound 6 displayed the strongest NO inhibitory effect with IC50 value of 15.9 μM, and compound 15 with IC50 of 20.2 μM. The two compounds not only decreased IL-1β and TNF-α levels in RAW264.7 cells and HK-2 cells, but also downregulated the levels of NLRP3, P-NF-κB p65 and HMGB1 in activated HK-2 cells in a dose-dependent manner. Second, in the renal protection assay with H2O2-stimulated HK-2 cell line, they reduced MDA level and increased SOD in HK-2 cells; additionally, they also inhibited the HK-2 cell apoptosis and downregulated the Caspase-1 p20 level. Third, in the in vivo activity tests of the septic mouse, they also showed good activities just like in vitro, decreasing the IL-1β, TNF-α, MDA, blood creatinine (Scr) and urea nitrogen (BUN) in serum, and increasing SOD levels in a dose-dependent manner. The immunoblotting results showed the two compounds downregulated the levels of HMGB1, P-NF-κB p65, NLRP3 and Caspase-1 p20 protein. All in all, the two compounds improved the renal injury of septic mice, and alleviated the tube wall structure damage and renal tubular dilation in kidney, which further proved by H&E staining. This suggests the two compounds have septic acute kidney injury activity, and they will be potential therapeutic drugs for septic acute kidney injury.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为HMGB1抑制剂的甘草甜素类似物的合成及其对急性肾损伤败血症的活性。
甘草酸(GL)是一种高度保守核蛋白(HMGB1)的拮抗剂。研究表明,GL的糖基是GL与HMGB1结合的重要药效团,是其作用机制的决定因素。为了获得具有较高活性和良好药代动力学特性的HMGB1抑制剂,合成了两类含有C-N糖苷键的GL类似物,并对其抗炎、抗氧化应激和抗脓毒性肾损伤进行了评价。结果如下。首先,在抗炎试验中,所有化合物都在一定程度上抑制了NO的释放;其中,化合物6对NO的抑制作用最强,IC50为15.9μM,化合物15的IC50为20.2μM。这两个化合物不仅降低了RAW264.7细胞和HK-2细胞中IL-1β和TNF-α的水平,而且以剂量依赖的方式下调了活化的HK-2细胞的NLRP3、P-NF-κB p65和HMGB1的水平。第二,在H2O2刺激的HK-2细胞系的肾保护试验中,它们降低了HK-2细胞的MDA水平,增加了SOD;此外,它们还抑制HK-2细胞凋亡并下调Caspase-1p20水平。第三,在脓毒症小鼠的体内活性测试中,它们也显示出与体外一样的良好活性,降低了血清中的IL-1β、TNF-α、MDA、血肌酐(Scr)和尿素氮(BUN),并以剂量依赖的方式提高了SOD水平。免疫印迹结果显示,这两种化合物下调了HMGB1、P-NF-κB p65、NLRP3和Caspase-1 p20蛋白的水平。总之,这两种化合物改善了脓毒症小鼠的肾损伤,减轻了肾小管壁结构损伤和肾小管扩张,H&E染色进一步证明了这一点。这表明这两种化合物具有感染性急性肾损伤活性,它们将是治疗感染性急性肾脏损伤的潜在药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Discovery of Potent and Selective Factor XIa Inhibitors Incorporating Triazole-Based Benzoic Acid as Novel P2’ Fragments: Molecular Dynamics Simulations and Anticoagulant Activity Design, synthesis, and biological evaluation of novel highly potent FXR agonists bearing piperidine scaffold Design, synthesis and anti-tumor evaluation of novel pyrimidine and quinazoline analogues Optimization of SHP2 Allosteric Inhibitors with Novel Tail Heterocycles and Their Potential as Antitumor Therapeutics Discovery of a Highly Potent, N-terminal Domain-targeting degrader of AR-FL/AR-V7 for the treatment of Prostate Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1